205 related articles for article (PubMed ID: 25145802)
1. Some inconsistencies in NICE's consideration of social values.
Paulden M; O'Mahony JF; Culyer AJ; McCabe C
Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
[TBL] [Abstract][Full Text] [Related]
2. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
[TBL] [Abstract][Full Text] [Related]
3. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
O'Mahony JF; Paulden M
Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
[TBL] [Abstract][Full Text] [Related]
4. Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?
Paulden M
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):239-242. PubMed ID: 28490259
[No Abstract] [Full Text] [Related]
5. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
[TBL] [Abstract][Full Text] [Related]
6. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
7. The NICE cost-effectiveness threshold: what it is and what that means.
McCabe C; Claxton K; Culyer AJ
Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
[TBL] [Abstract][Full Text] [Related]
8. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
McKenna C; Maund E; Sarowar M; Fox D; Stevenson M; Pepper C; Woolacott N; Palmer S
Pharmacoeconomics; 2012 Jan; 30(1):35-46. PubMed ID: 22136303
[TBL] [Abstract][Full Text] [Related]
9. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
Boyers D; Jia X; Jenkinson D; Mowatt G
Pharmacoeconomics; 2012 Jun; 30(6):483-95. PubMed ID: 22480381
[TBL] [Abstract][Full Text] [Related]
11. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.
Hale G; Morris J; Barker-Yip J
J Comp Eff Res; 2023 Nov; 12(11):e230093. PubMed ID: 37724717
[No Abstract] [Full Text] [Related]
12. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?
Getsios D; Migliaccio-Walle K; Caro JJ
Pharmacoeconomics; 2007; 25(12):997-1006. PubMed ID: 18047386
[TBL] [Abstract][Full Text] [Related]
13. Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Jones-Hughes T; Dunham J; Warren FC; Robinson S; Stephens P; Hoyle M
Pharmacoeconomics; 2018 Jan; 36(1):39-49. PubMed ID: 28914440
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
Chen G; Peirce V; Marsh W
Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
[TBL] [Abstract][Full Text] [Related]
15. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
17. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
Devlin N; Parkin D
Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
[TBL] [Abstract][Full Text] [Related]
18. Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.
Lord J; Willis S; Eatock J; Tappenden P; Trapero-Bertran M; Miners A; Crossan C; Westby M; Anagnostou A; Taylor S; Mavranezouli I; Wonderling D; Alderson P; Ruiz F
Health Technol Assess; 2013 Dec; 17(58):v-vi, 1-192. PubMed ID: 24325843
[TBL] [Abstract][Full Text] [Related]
19. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
Wang S; Gum D; Merlin T
Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
[TBL] [Abstract][Full Text] [Related]
20. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
